PATRICIA: A Phase II Clinical Trial of Combined Palbociclib and Trastuzumab, With or Without Letrozole, in Post-menopausal Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer

Trial Profile

PATRICIA: A Phase II Clinical Trial of Combined Palbociclib and Trastuzumab, With or Without Letrozole, in Post-menopausal Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Palbociclib (Primary) ; Letrozole; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms PATRICIA
  • Most Recent Events

    • 12 Sep 2017 To date, 43 patients, 13 in A and 15 in each B cohort, have been included in 14 sites across Spain, The first stage efficacy analysis is intended for December 2017 as per trial design presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress
    • 05 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top